Matthias Hepprich

Basel, BS 4031, Switzerland

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 27 publications

Immunometabolic endotypes define distinct clinical trajectories in type 2 diabetes.

Immunometabolic endotypes define distinct clinical trajectories in type 2 diabetes.

Journal: Cell metabolism

Published: June 08, 2026

Acute interleukin-1β antagonism decreases systemic inflammation, increases GLP-1 release, and modulates insulin secretion in individuals with prediabetes.

Acute interleukin-1β antagonism decreases systemic inflammation, increases GLP-1 release, and modulates insulin secretion in individuals with prediabetes.

Journal: American journal of physiology. Endocrinology and metabolism

Published: March 04, 2026

The power of lifestyle intervention to induce glycaemic control in a patient with newly diagnosed type 2 diabetes and HbA1c >10.

The power of lifestyle intervention to induce glycaemic control in a patient with newly diagnosed type 2 diabetes and HbA1c >10.

Journal: Endocrinology, diabetes & metabolism case reports

Published: December 14, 2025

Type 2 diabetes subphenotypes are associated with differential outcomes after metabolic and bariatric surgery: An international multicentre retrospective cohort study.

Type 2 diabetes subphenotypes are associated with differential outcomes after metabolic and bariatric surgery: An international multicentre retrospective cohort study.

Journal: Diabetes, obesity & metabolism

Published: December 06, 2025

Canakinumab for the treatment of postprandial hypoglycaemia: study protocol for a randomised, placebo-controlled, parallel-group, double-blind, multicentric, superiority trial-the CanpHy study.

Canakinumab for the treatment of postprandial hypoglycaemia: study protocol for a randomised, placebo-controlled, parallel-group, double-blind, multicentric, superiority trial-the CanpHy study.

Journal: BMJ open

Published: May 27, 2025

GIP/GLP-1RA as adjunctive to automated insulin delivery in adults with Type 1 diabetes (the AID-JUNCT trial): Study protocol for a prospective, randomized, clinical trial.

GIP/GLP-1RA as adjunctive to automated insulin delivery in adults with Type 1 diabetes (the AID-JUNCT trial): Study protocol for a prospective, randomized, clinical trial.

Journal: PloS one

Published: May 12, 2025

Exenatide for diagnosing endogenous hyperinsulinemic hypoglycemia: a randomized placebo-controlled, double-blind, cross-over proof-of-principle study.

Exenatide for diagnosing endogenous hyperinsulinemic hypoglycemia: a randomized placebo-controlled, double-blind, cross-over proof-of-principle study.

Journal: European journal of endocrinology

Published: March 31, 2025

Blood Characteristics of Adults With Type 2 Diabetes and Response of Their Peripheral Blood Mononuclear Cells to Inhibitors of the NLRP3 Inflammasome and Caspase-1.

Blood Characteristics of Adults With Type 2 Diabetes and Response of Their Peripheral Blood Mononuclear Cells to Inhibitors of the NLRP3 Inflammasome and Caspase-1.

Journal: Canadian journal of diabetes

Published: March 18, 2025

Dyslipidaemia and growth hormone deficiency - A comprehensive review.

Dyslipidaemia and growth hormone deficiency - A comprehensive review.

Journal: Best practice & research. Clinical endocrinology & metabolism

Published: October 11, 2023

Arachidonic acid inhibition of the NLRP3 inflammasome is a mechanism to explain the anti-inflammatory effects of fasting.

Arachidonic acid inhibition of the NLRP3 inflammasome is a mechanism to explain the anti-inflammatory effects of fasting.

Journal: Cell reports

Published: August 10, 2023

Awareness and knowledge of diabetic ketoacidosis in people with type 1 diabetes: a cross-sectional, multicenter survey.

Awareness and knowledge of diabetic ketoacidosis in people with type 1 diabetes: a cross-sectional, multicenter survey.

Journal: BMJ open diabetes research & care

Published: July 28, 2023

Randomized, Double-Blind, Placebo-Controlled Crossover Trial of Once Daily Empagliflozin 25 mg for the Treatment of Postprandial Hypoglycemia After Roux-en-Y Gastric Bypass.

Randomized, Double-Blind, Placebo-Controlled Crossover Trial of Once Daily Empagliflozin 25 mg for the Treatment of Postprandial Hypoglycemia After Roux-en-Y Gastric Bypass.

Journal: Diabetes technology & therapeutics

Published: April 24, 2023

Showing 1-12 of 27

Last Updated: 09/26/2026